Inhibrx Biosciences' (INBX) "Market Perform" Rating Reiterated at JMP Securities

Key Points

• JMP Securities has reiterated a “market perform” rating for Inhibrx Biosciences (NASDAQ:INBX), indicating cautious optimism.
• Wall Street Zen upgraded the company from a "sell" to a "hold" rating, aligning with the current consensus rating of "hold" among analysts.
• Inhibrx reported an EPS of ($1.85) for its recent quarter, surpassing the consensus estimate of ($2.92) by $1.07, with revenues of $1.30 million.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report)'s stock had its "market perform" rating restated by JMP Securities in a research report issued to clients and investors on Friday,Benzinga reports.

Separately, Wall Street Zen upgraded Inhibrx Biosciences from a "sell" rating to a "hold" rating in a report on Sunday, August 17th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has a consensus rating of "Hold".

Inhibrx Biosciences Price Performance

NASDAQ INBX opened at $24.16 on Friday. Inhibrx Biosciences has a one year low of $10.81 and a one year high of $25.29. The stock has a 50-day moving average of $20.10 and a 200 day moving average of $15.39. The company has a market capitalization of $349.84 million, a price-to-earnings ratio of -2.28 and a beta of 0.24. The company has a debt-to-equity ratio of 1.45, a quick ratio of 4.98 and a current ratio of 4.98.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($1.85) EPS for the quarter, topping the consensus estimate of ($2.92) by $1.07. The business had revenue of $1.30 million during the quarter. On average, sell-side analysts forecast that Inhibrx Biosciences will post 104.88 EPS for the current year.

Institutional Investors Weigh In On Inhibrx Biosciences

A number of large investors have recently made changes to their positions in INBX. Strs Ohio bought a new position in shares of Inhibrx Biosciences during the 1st quarter valued at approximately $27,000. Natixis bought a new position in shares of Inhibrx Biosciences during the 4th quarter valued at approximately $31,000. State of Wyoming bought a new position in shares of Inhibrx Biosciences during the 4th quarter valued at approximately $83,000. Wells Fargo & Company MN bought a new position in shares of Inhibrx Biosciences during the 4th quarter valued at approximately $102,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Inhibrx Biosciences during the 4th quarter valued at approximately $102,000. 82.46% of the stock is currently owned by institutional investors.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.